Table 4: Arsenic dermal exposure and risk characterization for adults & children.
Average Daily Intake (ADII) | Risk characterization | Hazard Quotient (HQ) | ||||||
Carcinogenic | Non-carcinogenic | Carcinogenic Risk (CR) | Non-carcinogenic Risk | |||||
Treatment | Control | Treatment | Control | Treatment | Control | Treatment | Control | |
Scenario 3: (Adults Male Dermal absorption Agriculture use) | ||||||||
Adubriem | 1.00E-05 | 2.17E-06 | 2.50E-05 | 5.40E-06 | 1.50E-05 | 3.26E-06 | 0.08 | 0.02 |
T3 | 3.25E-06 | 1.46E-06 | 8.13E-06 | 3.65E-06 | 4.87E-06 | 2.19E-06 | 0.03 | 0.01 |
T1 | 2.15E-05 | 4.89E-06 | 5.37E-05 | 1.22E-05 | 3.23E-05 | 7.34E-06 | 0.18 | 0.04 |
Nhyiaeso | 1.60E-05 | 4.89E-06 | 3.86E-05 | 1.22E-05 | 2.40E-05 | 7.34E-06 | 0.13 | 0.04 |
Sansu | 1.03E-05 | 4.89E-06 | 2.58E-05 | 1.22E-05 | 1.55E-05 | 7.34E-06 | 0.09 | 0.04 |
Scenario 4: (Adults Female Dermal absorption Agriculture) | ||||||||
Adubriem | 8.65E-06 | 1.87E-06 | 2.16E-05 | 4.67E-06 | 1.29E-05 | 2.82E-06 | 0.07 | 0.02 |
T3 | 2.81E-06 | 1.26E-06 | 7.03E-06 | 3.16E-06 | 4.21E-06 | 1.89E-06 | 0.03 | 0.01 |
T1 | 1.85E-05 | 4.23E-06 | 4.64E-05 | 1.06E-05 | 2.79E-05 | 6.34E-06 | 0.16 | 0.03 |
Nhyiaeso | 1.38E-05 | 4.23E-06 | 3.34E-05 | 1.06E-05 | 2.08E-05 | 6.34E-06 | 0.11 | 0.03 |
Sansu | 8.91E-06 | 4.23E-06 | 2.23E-05 | 1.06E-05 | 1.34E-05 | 6.34E-06 | 0.08 | 0.03 |
Scenario 5: (Children Dermal absorption Agriculture) | ||||||||
Adubriem | 4.36E-05 | 9.41E-06 | 1.09E-04 | 2.35E-05 | 6.54E-05 | 1.41E-05 | 0.36 | 0.08 |
T3 | 1.41E-05 | 6.36E-06 | 3.52E-05 | 1.59E-05 | 2.12E-05 | 9.54E-06 | 0.12 | 0.05 |
T1 | 4.48E-04 | 2.12E-05 | 2.34E-04 | 5.30E-05 | 6.72E-04 | 3.18E-05 | 0.78 | 0.18 |
Nhyiaeso | 9.35E-06 | 2.12E-05 | 1.68E-04 | 5.30E-05 | 1.40E-05 | 3.18E-05 | 0.56 | 0.18 |
Sansu | 4.38E-05 | 2.12E-05 | 1.12E-04 | 5.30E-05 | 6.57E-05 | 3.18E-05 | 0.37 | 0.18 |
All treatment sites (reclaimed) are backfilled Pits or waste dumps with waste material dumped adjacent to the pit used for backfilling.